← Leaderboards
Jennifer Baltz
I-Cordis, Llc
$1,824,935
Attributed
$1,824,935
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $808.8K · FY2019–23$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$1,824,935 · 2
By mechanism
R44$1,548,708 · 1
R43$276,227 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Property”
- Valerie Koch · University Corporation For Atmospheric Res$247,762,266
- Susan Abushakra · Alzheon, Inc.$47,265,244
- John Hobbs · Suny At Stony Brook$42,194,917
- Christopher Bee · Suny At Stony Brook$41,239,084
- John Damon Chodera · Sloan-Kettering Inst Can Research$39,689,447
- Eric C Palm · Florida State University$35,115,872
Research focus
PropertyBiological AvailabilityImmunoregulationPre-ClinicalSide EffectToxicologyHalf-LifeHeart FailurePersonsPlasmaFda ApprovedPyridonesSmall Business Innovation Research GrantSmall MoleculeCommercializationDrug KineticsHealth Care CostsCardioprotectionLung DiseasesOralPharmaceutical PreparationsPirfenidoneCanis FamiliarisExposure To
Grant awards (3)
Development of a Novel Immunomodulatory Pyridone for the Treatment of Heart Failure with Preserved Ejection Fraction$739,896
R44 · FY2023 · HL · contact PI
Development of a Novel Immunomodulatory Pyridone for the Treatment of Heart Failure with Preserved Ejection Fraction$808,812
R44 · FY2022 · HL · contact PI
Development of a novel immunomodulatory pyridone for the treatment of acute heart damage$276,227
R43 · FY2019 · HL · contact PI